Grant: Collaborative Health Research Projects
Queen's University
$180,400.00
Development of antibody-drug conjugates that use actin-targeting warheads
FY 2018-19
Summary
Cancer metastasis involves the spread of cancer cells from one organ to another and is the*cause of 90% of cancer-related deaths. Current therapies fail to block metastasis effectively,*and our invention of novel actin-targeted ADCs will address this unmet need. Dynamic*modifications of the actin cytoskeleton are essential for cancer cells to breakthrough tissue*and blood vessel barriers during metastasis. Targeting this ""actin addiction"" is the goal of this*project, which is built on our detailed knowledge of potent natural inhibitors of actin. Our*multidisciplinary team has designed, synthesized and tested novel actin toxin analogs that*block growth, motility and invasion of metastatic cancer cells in vitro. Currently, we are linking*these to antibodies used in oncology, and will test these novel ADCs in preclinical mouse*models of metastatic cancers relevant to each clinically used antibody. These studies will*measure effects of our ADCs on tumour progression and metastasis.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
508358-2017
Name nom
Allingham, John
Department département
Biomedical and Molecular Sciences
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
180400
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Development of antibody-drug conjugates that use actin-targeting warheads
Keyword
NSERC
Application summary
Cancer metastasis involves the spread of cancer cells from one organ to another and is the*cause of 90% of cancer-related deaths. Current therapies fail to block metastasis effectively,*and our invention of novel actin-targeted ADCs will address this unmet need. Dynamic*modifications of the actin cytoskeleton are essential for cancer cells to breakthrough tissue*and blood vessel barriers during metastasis. Targeting this ""actin addiction"" is the goal of this*project, which is built on our detailed knowledge of potent natural inhibitors of actin. Our*multidisciplinary team has designed, synthesized and tested novel actin toxin analogs that*block growth, motility and invasion of metastatic cancer cells in vitro. Currently, we are linking*these to antibodies used in oncology, and will test these novel ADCs in preclinical mouse*models of metastatic cancers relevant to each clinically used antibody. These studies will*measure effects of our ADCs on tumour progression and metastasis.
